Veracyte, Inc.

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US92337F1075
USD
47.41
1.25 (2.71%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Veracyte, Inc. stock-summary
stock-summary
Veracyte, Inc.
Pharmaceuticals & Biotechnology
Veracyte, Inc. is a genomic diagnostics company. The Company, through its scientific platform, which utilizes ribonucleic acid (RNA), whole-transcriptome sequencing combined with machine learning, produces genomic tests. It provides various genomic tests, including Afirma Genomic Sequencing Classifier (GSC), Percepta Bronchial Genomic Classifier, Envisia Genomic Classifier and Afirma Xpression Atlas. It provides GSC tests for thyroid cancer. It provides Percepta Bronchial Genomic Classifier tests for lung cancer. It provides Envisia Genomic Classifier tests for idiopathic pulmonary fibrosis (IPF). Its Afirma Xpression Atlas provides information on gene alterations associated with thyroid cancer, enabling physicians to tailor surgical and treatment decisions at time of diagnosis.
Company Coordinates stock-summary
Company Details
6000 Shoreline Ct Ste 300 , SOUTH SAN FRANCISCO CA : 94080-7606
stock-summary
Tel: 1 650 24363001 650 3804413
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 87 Schemes (53.53%)

Foreign Institutions

Held by 147 Foreign Institutions (17.6%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Ms. Bonnie Anderson
Chairman of the Board, Chief Executive Officer
Mr. John Bishop
Lead Independent Director
Mr. Jens Holstein
Director
Dr. Frederick Cohen
Independent Director
Ms. Karin Eastham
Independent Director
Dr. Robert Epstein
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
130 Million
(Quarterly Results - Jun 2025)
Net Profit:
-1 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 2,554 Million (Small Cap)

stock-summary
P/E

56.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.26

stock-summary
Return on Equity

4.10%

stock-summary
Price to Book

2.09